PCa Screening New Areas of Research Francesco Montorsi Milan.

Slides:



Advertisements
Similar presentations
The Great PSA Testing Controversy Does PSA Testing Do More Harm Than Good? Associate Professor Anthony Lowe.
Advertisements

HEALTHY PEOPLE. Aims  Interpret evidence about a screening programme and decide whether it is worthwhile – for individuals or groups  Demonstrate an.
PSA Testing William J Catalona MD Northwestern University.
RESULTS TITLE; Prospective randomized controlled trial of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening protocol.
Prostate Cancer Detection in Men with an Initial Diagnosis of Atypical small Acinar Proliferations Dr Charles Chabert The Wollongong Hospital.
Epidemiology of prostate cancer Epidemiology and Molecular Pathology of Cancer: Bootcamp course Tuesday, 3 January 2012.
The DASH Study Patrick Leonberger MSIV BGSMC Nov 8, 2013.
Prostate Cancer Screening: Con
Meta-Analysis of PSA Growth Lurdes Y.T. Inoue, Ph.D. Ruth Etzioni, Ph.D. Elizabeth Slate, Ph.D. Christopher Morrel, Ph.D.
High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.
Prostate Cancer One of the commonest causes of death in the Western World USA 2005 – 232,090 new cases – 30,350 deaths Lifetime risk of disease 16.6% Lifetime.
Otis W. Brawley, M.D. Chief Medical and Scientific Officer Executive Vice President American Cancer Society Professor of Hematology, Medical Oncology,
A PRACTICAL GUIDE TO PSA SCREENING Kendall Itoku, MD St. Louis Urological Surgeons.
Clinical Practice Screening for Colorectal Cancer David A. Lieberman, M.D. N Engl J Med Volume 361(12): September 17, 2009.
Geriatric Health Maintenance: Cancer Screening Linda DeCherrie, MD Geriatric Fellow Mount Sinai Hospital.
Prostates & Pissing in the Wind. The Laytons Bob December 25, 1925 – May 9, 2002 Jack July 18, 1950 – August 22, 2011.
Cancer Genetics. Issues Colorectal guidelines – Awaiting publication of coloproctologists guidance – SIGN / QIS update started Breast / ovarian – Breast.
Prostate Cancer Screening 2012 Paul L. Crispen, MD Department of Surgery University of Kentucky.
Prostate Cancer Screening Assistant Professor Charles Chabert Men’s health Seminar Ballina April 2011 prostates.com.au.
M Ravanbod Medical oncologist Bushehr – 11/91 A 50 y/o white man comes for check up and wants to discuss about prostate cancer. Negative family history.
How to Overcome Barriers and Develop Collaborative Guidelines Amir Qaseem, MD, PhD, MHA, FACP Chair, Guidelines International Network Director, Clinical.
© 2010 Pearson Prentice Hall. All rights reserved Chapter Data Collection 1.
Multiple Choice Questions for discussion
EPCA: A silver lining for early diagnosis of prostate cancer GHOLAMREZA POURMAND, MD Professor of Urology Urology Research Center Tehran University of.
Prostate Cancer James B. Benton,M.D.. Prostate Cancer Significant of the clinical problem Early detection/screening Prevention/Management.
Should I have that blood test for Prostate Cancer?
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
A/Prof Brian Cox Cancer Epidemiologist Dunedin. Research Associate Professor Brian Cox Hugh Adam Cancer Epidemiology Unit Department of Preventive and.
Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.
Prostate Cancer Screening in 2013: Reports of its Death Are Greatly Exaggerated Norm D. Smith, M.D. Associate Professor Co-Director Urologic Oncology University.
Urology Update Sanofi- Aventis
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.
All about PSA (not Pharmaceutical Society of Australia)
Biostatistics Case Studies Peter D. Christenson Biostatistician Session 2: Diagnostic Classification.
“The African American Prostate Cancer Crisis in Numbers”
Biomarkers in Prostate Cancer Prostate Cancer Symposium The Prostate Net September 17, 2011 Steven Lucas Wayne State University School of Medicine Karmanos.
Prostate Cancer Screening in African American Men Mark H. Kawachi, MD FACS Director, Prostate Cancer Center City of Hope, National Medical Ctr.
Impact of Socioeconomic Status on Cardiovascular Disease and Mortality in 24,947 Individuals With Type 1 Diabetes Featured Article: Araz Rawshani, Ann-Marie.
Prostate Cancer Coalition of NC A statewide collaborative effort by concerned organizations and individuals to support awareness, early detection, and.
PSA Testing Importance of Multiple Markers Ian Thompson MD Department of Urology University of Texas HSC San Antonio, TX.
A Clinical Profile of Male Health in the Bahamas “Real Men Die from Prostate Cancer” A Clinical Profile of Male Health in the Bahamas “Real Men Die from.
Prostate Cancer Screening Risk Management Ben Inch.
Prostate Screening in the New Millennium Dr Pamela Ajayi MD PathCare.
Il PSA nello screening del carcinoma della prostata PRO Franco Gaboardi Urologia Ospedale San Raffaele Turro Milano.
MpMRI in Prostate cancer A Urologist’s Perspective Diagnosis Treatment Choice Surgical Planning Dr. Peter Heathcote, Adjunct Professor APCRC-Q QUT, Senior.
Diabetes and Cause-Specific Mortality in a Prospective Cohort of One Million U.S. Adults Featured Article: Peter T. Campbell, Ph.D., Christina C. Newton,
Per-Anders Abrahamsson, Department of Urology Malmö University Hospital Sweden EAU, Berlin, March 24, 2007 What´s New in Prostate Cancer?
South West Public Health Observatory The changing casemix of prostate cancer patients and prostatectomies in the South West Sean McPhail.
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
PSA screening Cost Conscious Project Kristopher Huston January 2016.
What are the Chances Dr? Nick Pendleton. Can I have a Prostate Check? ?
Variation in place of death from cancer: studies in South East England Elizabeth Davies, Peter Madden, Victoria Coupland, Karen Linklater, Henrik Møller.
PSA Consensus and The Prostate Cancer Risk Management Programme Karen Stalbow, Prostate Cancer UK Dr Ali Cooper, Prostate Cancer UK Annual Conference 2016.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Risk-adapted prostate cancer (PCa) early detection study based on a “baseline” PSA value in young men – a prospective multicenter randomized trial (PROBASE)
RELAZIONE TRA “STAGE MIGRATION” E
International Neurourology Journal 2013;17:73-77
Definition of Cancer Screening
2017 USPSTF Draft Recommendations for Prostate Cancer Screening
Dr. John Jordan Dr. Stephen Pautler
Prevention and Early Diagnosis of Cancer Ongar Health Centre Patient Forum 7th March 2018 Sue White Cancer Research UK Facilitator.
Volume 73, Issue 6, Pages (June 2018)
Volume 183, Issue 3, Pages (March 2010)
Willie Underwood, III, MD, MS,MPH
Prostate Cancer Screening- Update
Active Surveillance for Low Risk Prostate Cancer
the SNP profile using 26 prostate cancer GWAS risk SNPs
Thomas Steuber, Matthew Frank O'Brien, Hans Lilja  European Urology 
Prostate cancer screening beyond PSA – STHLM3 and/or MRI
Presentation transcript:

PCa Screening New Areas of Research Francesco Montorsi Milan

Ullmert D; BMC Med Feb 15;6:6 In 1974–1986 blood samples were obtained from a cohort of 21,277 men aged up to 50 Through 1999, 498 men were diagnosed with prostate cancer, and of these 161 had locally advanced or metastatic prostate cancers Three controls, matched for age and date of venipuncture, were selected for each case. Conditional logistic regression was used to test associations between molecular markers and advanced cancer The Malmö Preventive Project (mPP)

Ullmert D; BMC Med Feb 15;6:6 Two-thirds of the advanced cancer cases occurred in men with the top 20% of PSA levels (0.9 ng/ml or higher) The Malmö Preventive Project (mPP)

Men who had PSA values at or below 1.2 ng/ml at age 60 had a 0.3% risk of prostate cancer death by age 85. The risk of dying of prostate cancer by age 85 increased to: 1.5% in men whose PSA value was 1.5 ng/mL at age 60 (67th percentile). 3.7% in men who had a PSA level of 2.1 ng/mL at age 60 (80th percentile). 8.9% in men who had a PSA level from 2.1 to 3.4 ng/mL at age 60 (90th percentile) 15% in men who had a PSA level of 5.2 ng/mL at age 60 (95th percentile) 31% in men who had a PSA level of 15 ng/mL (at age 60 99th percentile). Lilja H et al AUA Meeting, Chicago, 2009 PSA at Age 60 Predicts Prostate cancer Mortality by 85 The Malmö Preventive Project (mPP)

Sixty-year-old men with PSA at or below the population median can be advised that although they may harbor cancer, it is unlikely to become life threatening Those with PSA elevated above thresholds such as 3 or 4 ng/mL are at greatly increased risk of clinically diagnosed prostate cancer and prostate cancer- specific death CONCLUSIONS BY DR LILJA Lilja H et al AUA Meeting, Chicago, 2009 The Malmö Preventive Project (mPP)

Median PSA level: men aged was 0.7 ng/mL men aged was 0.9 ng/mL Baseline PSA value (age <60 years old) Prostate cancer rate <0.7 ng/mL0.4% ng/mL4.1% ng/mL18.9% ng/mL29.1% >10.0 ng/mL50.0% Loeb S. et al. Urology 2006,67:316–320

Baseline PSA level was a significant predictor of CaP diagnosis

Baseline PSA in PCa patients yo

Loeb S. et al. Urology 2006,67:316–320

Tang P et al, J Urol 2010;183, An initial PSA cutoff of 1.5 ng/ml may be better than median PSA 0.7 ng/ml to determine the risk of PCa in men ≤50 years old

Increased Risk of PCa in FU years in men with baseline PSA > or < 1.5 Tang P et al, J Urol 2010;183,

Robool et al, J Urol 2009; 182: Examination of a greater number of data sets suggests that for men 50 to 70 years a PSA greater than 1.5 ng/ml is a marker for greater risk of PCa in the short to medium term (up to 8 years), These men are at 7.5-times greater risk for prostate cancer than those with PSA less than 1.5 ng/ml. For younger men with longer follow-up a lower PSA should be considered. In addition, the PSA threshold should be lower for men with a prostate volume less than 40 cc, black ethnicity or a family history of prostate cancer.

AUA Prostate Cancer Guidelines 2009

“It seems reasonable to obtain a baseline PSA testing at age 40 to assess the risk for further PCa detection” NCCN Prostate Cancer Guidelines 2010

CONCLUSIONS Initial evidence is suggesting that men in their years represent a population who needs to be investigated It would be interesting to study both men with and without a family history of PCa